Improved Disability, Cognition With Ocrelizumab in MS Improved Disability, Cognition With Ocrelizumab in MS

Extension data from phase 3 clinical trials show greater improvements in patients who continued receiving ocrelizumab than in those who switched from interferon beta-1a.Medscape Medical News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Neurology & Neurosurgery News Source Type: news